PRE

Prenetics Global Limited Class A Ordinary Share

17.23

USD

-0.32

-1.82%

Nov 10, 15:59 UTC -5

Closed

After-Market

17.29

+0.05

+0.32%

Prenetics Global Limited Class A Ordinary Share (PRE) Earnings

PRE Earnings Reports

Positive Surprise Ratio

PRE beat 7 of 15 last estimates.

47%

Next Report

Date of Next Report

Feb 16, 2027

Estimate for Q4 26 (Revenue/ EPS)

$79.35M

-$0.68

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+117.05%

-61.14%

Prenetics Global Limited Class A Ordinary Share earnings per share and revenue

On Nov 09, 2026, PRE reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.82 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 63.82 million, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.68 USD, with revenue projected to reach 79.35 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Prenetics Global Limited Class A Ordinary Share's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Prenetics Global Limited Class A Ordinary Share reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Prenetics Global Limited Class A Ordinary Share's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Prenetics Global Limited Class A Ordinary Share expected to report next?

The next earning report is scheduled for Feb 16, 2027.

What are the forecasts for Prenetics Global Limited Class A Ordinary Share's next earnings report?

Based on -- analysts, Prenetics Global Limited Class A Ordinary Share is expected to report EPS of -$0.68 and revenue of $79.35M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.